PROSTA SPÓŁKA AKCYJNA
Revify Devops
Revify Devops Prosta Spółka Akcyjna
PROSTA SPÓŁKA AKCYJNA
Revify Devops Prosta Spółka Akcyjna
Revify Devops Prosta Spółka Akcyjna (KRS 0000994524, NIP 5170429578) is a Polish company, headquartered in Rzeszów, Podkarpackie voivodeship. REVIFY DEVOPS operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since October 3, 2022.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Credibility rating
54.1 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
3
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/4 yrs
Board changes
0
0/4 yrs
PKD changes
0
0/4 yrs
Name changes
0
0/4 yrs
Data from 4 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
October 3, 2022
3 years in operation
Legal form
PROSTA SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
RZESZÓW
PODKARPACKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
N/A
Shareholders
N/A
Board
2 people
Sup. board: 2
Filed years
1 year
2023
Registry entries
5
latest: July 15, 2025
Revenue
N/A
2023
Net profit
0 PLN
2023
Assets
100 PLN
2023
Equity
100 PLN
2023
Rate business credibility - Revify Devops.
No ratings

News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.

News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
REVIFY DEVOPS's board has 2 members.
5 historical registry entries for Revify Devops
Registration in the Polish National Court Register
RZ.XII NS-REJ.KRS/14588/22/580
Identifier change
RZ.XII NS-REJ.KRS/14588/22/580/NIP
Identifier change
RZ.XII NS-REJ.KRS/14588/22/580/REGON
Filing document
Filing document
Latest reporting year
2024
Available years
2
Filing entries
0
Competing companies or those operating in the same market segment as Revify Devops (in Rzeszów, industry: Research and development).
MIELEC· Research and development
Revenue 2024: 60.0 M PLN
MIELEC· Research and development
Revenue 2024: 37.7 M PLN
RZESZÓW· Research and development
Revenue 2024: 11.2 M PLN
RZESZÓW· Research and development
Revenue 2024: 11.0 M PLN
JASIONKA· Research and development
Revenue 2022: 2.2 M PLN
STRZYŻÓW· Research and development
Revenue 2024: 2.1 M PLN